Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting
NCT07208305Phase 3Recruiting
- Sponsor
- Affiliated Hospital of Qinghai University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine, metoclopramide in Opioid-induced nausea and vomiting (OINV), sponsored by Affiliated Hospital of Qinghai University. Started Feb 2026; status: recruiting.
02
Drugs
olanzapinemetoclopramide
03
Conditions
Opioid-induced nausea and vomiting (OINV)
Beyond the preview
Go deeper on NCT07208305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208305.